RD 765/35316 – Clinical Trials UK Skip to content


If you are a healthy male or female (of non-childbearing potential) aged between 18 and 50, then you may be eligible to participate in a clinical trial investigating a treatment being developed for Parkinson’s Disease. 

Maximum Inconvenience Payment of £3,225.00. 

study information

Simbec-Orion Clinical Pharmacology will soon be running a study to investigate a potential new treatment for Parkinson’s Disease (PD) called BIIB122/DNL151. 

BIIB122/DNL151 is being developed as a potential treatment for Parkinson’s Disease (PD). PD is a long-term progressive condition of the nervous system whereby there is an accumulation of proteins in certain cells in the brain, leading to death of these cells. These cells control and manage the signals from the brain to the body which control movement. Therefore, as these cells die, symptoms begin to appear. PD is associated with shaking/uncontrollable movements, rigidity in the muscles, slowness of movement and difficulty in walking.

Despite the development of effective therapies for PD, these treatments only serve to manage the symptoms associated with PD and do not actually address the underlying cause of the disease. Therefore, there is an unmet need to develop therapies which actively seek to target the underlying causes of the disease.


This study is classed as a drug-drug interaction study. This means that you will be given a drug which has known effects and a known method of breakdown (metabolism) in the body (midazolam) and then given the study drug (BIIB122/DNL151) to determine if there is any effect or interaction between the drugs in the body and whether administration of BIIB122/DNL151 affects the safety, tolerability and amount of midazolam in the blood. 

The purpose of the study is to evaluate the safety, tolerability and effect of BIIB122/DNL151 on the amount of midazolam in the blood to determine as to whether BIIB122/DNL151 has the potential to interact with other drugs which are broken down in the same way as midazolam, thereby affecting their desired effect in the body. 

In the study, participants will take a single dose of midazolam (2 milligrams – mg) on Day 1, followed by BIIB122/DNL151 once daily for 9 days (225 mg per dose) up to Day 10 before taking a single dose of both BIIB122/DNL151 and midazolam together on Day 11. 

If you participate in this study, you will be required to stay at the Simbec-Orion clinical unit for a maximum period of 13 days (12 overnight stays) followed by a post study follow-up visit on Day 15. Therefore, you should ensure that you are able to commit to completing all visits before agreeing to participate in this study.

Participants will be given BIIB122/DNL151 in the form of three 75 mg tablets per dose and midazolam will be administered in the form of an oral liquid solution.

Blood samples will be taken at set time points throughout the study in order to measure the amount of BIIB122/DNL151 and midazolam in the blood and to evaluate how the amount of midazolam differs when it is taken alone versus when it is taken with BIIB122/DNL151.

The purpose of this is to support the study sponsor in developing guidance as to how the BIIB122/DNL151 product should be administered in future clinical studies of the product and to develop an understanding as to how BIIB122/DNL151 may interact with other drugs.

study timeline

If you complete this study, you will receive a maximum inconvenience payment of £3,225.00. 


Thank you for your interest in joining our panel of healthy volunteers, please register by completing the below form.

This form does not exist